Piper Sandler Maintains Overweight Ratings on Boston Scientific, Colgate, Claritev, Phreesia Stocks

Piper Sandler has maintained its Overweight ratings on several prominent stocks, reflecting optimism about their future growth and financial health. Boston Scientific is highlighted for its strong momentum, with a 39% return over the past year and significant revenue growth driven by its electrophysiology franchise and devices like Watchman, positioning it for sustained double-digit growth. Colgate-Palmolive continues to manage tariff challenges effectively, with a stable financial outlook and geographic strengths supporting its $109 price target and Overweight rating. Claritev received an upgrade to Overweight with a price target increase to $44 following strong quarterly performance and strategic partnerships, despite concerns about cash burn and debt levels. Phreesia’s solid first-quarter earnings and increased EBITDA guidance underpin Piper Sandler’s confidence in its patient intake management solutions, with a price target of $33 and expectations of enhanced clinical outcomes and cost reductions through network effects. Overall, Piper Sandler’s analyses underscore confidence in these companies’ strategic positions and growth prospects amid varying market conditions.